Article Text

Download PDFPDF
124 Using HIPEC in ovarian cancer in Kazakh institute of oncology and radiology
  1. Alima Satanova,
  2. Yerlan Kukubassov,
  3. Dauren Kaldybekov,
  4. Orynbassar Bertleuov and
  5. Dilyara Kaidarova
  1. Kazakh Institute of Oncology and Radiology, Almaty, Kazakhstan


Introduction/Background In 2020, 313,959 new cases of OC were registered, 70% of which are registered at an advanced stage. In Kazakhstan, malignant neoplasms of the ovaries occupy the 8th ranking position among malignant tumors. The problem of OC treatment is extremely relevant for the Republic of Kazakhstan due to the significant prevalence of this disease among the female population. Despite the improvement in approaches to the diagnosis and treatment of OC, a high level of neglected cases and low 5-year survival rates in OC patients remain.

Methodology This study is a retrospective analysis of the outcomes of patients with ovarian cancer who underwent HIPEC at KazIOR from 2019 to 2023.

Results Since 2019, HIPEC has been performed in KazIOR for patients with ovarian cancer. From 2019 to 2023, 26 operations were performed, 19 (73%) of them in the volume of optimal cytoreduction, 7 (26%) operations in the volume of non-optimal cytoreduction, all operations were performed by abdominal access. 22 (84%) patients with stage 3c, 3 (11%) patient with stage 3b, 3 (11%) with stage 4a.

Concomitant diseases were in 21 (80%) patients of them: type 2 diabetes mellitus in 3 (14%) patients, arterial hypertension in 11 (52%) patients, chronic pyelonephritis in 3 (14%) patients, bronchial asthma in 1 (4.7%) of the patient, chronic bronchitis in 1 (4.7%) patient, chronic cholecystitis in 1 (4.7%) patient, moderate anemia in 1 (4.7%) patient.

In 2 (14%) patients, a complication after HIPEC in the form of acute renal failure was noted, 5 (19%) patients died from the progression of oncological disease.

Conclusion Considering the data for a four-year study, it can be argued that intra-abdominal hyperthermic chemotherapy is a safe treatment option for patients with ovarian cancer. Evaluation of effectiveness, overall and disease-free survival will be carried out after 5 years.

Disclosures No disclosures.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.